← Leaderboards
Shelby L Oconnor
University Of Wisconsin-Madison
$13,202,611
Attributed
$20,112,912
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,112,912 · 6
By mechanism
R01$19,606,368 · 4
R21$431,545 · 1
R13$74,999 · 1
Top collaborators
- Lishomwa C Ndhlovu8 shared
- Charles A. Scanga8 shared
- David H Oconnor3 shared
- Thomas C. Friedrich1 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- David H Oconnor$41,081,273
- James Romero-Masters$198,502
- Scott M Berry$6,162,635
- Thomas C. Friedrich$6,772,210
- Reid Spencer Alisch$3,126,578
Others in their field
Top investigators on “Animals”
- David Heimbrook · Leidos Biomedical Research, Inc.$534,904,829
- Richard Webby · St. Jude Children'S Research Hospital$259,408,394
- Eric S Lander · Whitehead Institute For Biomedical Res$209,574,154
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Richard K. Wilson · Washington University$130,501,539
- Mark S Klempner · Tufts Medical Center$129,182,794
Research focus
AnimalsMacacaInfectionImmune ResponseVirusT-LymphocyteCellsCytokineResponseDesignViralCell PhysiologyMonkeysMacaca FascicularisVaccinesImmuneImmunityNonhuman PrimateHiv InfectionsMediatingFutureCd4 Positive T LymphocytesPhenotypeAntiretroviral Therapy
Grant awards (26)
Characterizing the mechanism of post-treatment control of SIV in Mauritian cynomolgus macaques$790,348
R01 · FY2025 · AI · contact PI
Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection$784,938
R01 · FY2025 · AI
Anticipating and rapidly responding to respiratory virus outbreaks with continuous air sampling in K-12 schools$774,809
R01 · FY2025 · AI
Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection$793,149
R01 · FY2024 · AI
Anticipating and rapidly responding to respiratory virus outbreaks with continuous air sampling in K-12 schools$774,809
R01 · FY2024 · AI
Characterizing the mechanism of post-treatment control of SIV in Mauritian cynomolgus macaques$723,800
R01 · FY2024 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,200,666
R01 · FY2023 · AI
Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection$826,203
R01 · FY2023 · AI
Anticipating and rapidly responding to respiratory virus outbreaks with continuous air sampling in K-12 schools$788,684
R01 · FY2023 · AI
Characterizing the therapeutic efficacy of CD8 T cell responses induced by the IL-15 superagonist ALT-803$754,981
R01 · FY2023 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,216,647
R01 · FY2022 · AI
Characterizing the therapeutic efficacy of CD8 T cell responses induced by the IL-15 superagonist ALT-803$749,855
R01 · FY2022 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,213,831
R01 · FY2021 · AI
Characterizing the therapeutic efficacy of CD8 T cell responses induced by the IL-15 superagonist ALT-803$753,619
R01 · FY2021 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,218,191
R01 · FY2020 · AI
Characterizing the therapeutic efficacy of CD8 T cell responses induced by the IL-15 superagonist ALT-803$753,235
R01 · FY2020 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,301,851
R01 · FY2019 · AI
Characterizing the therapeutic efficacy of CD8 T cell responses induced by the IL-15 superagonist ALT-803$761,196
R01 · FY2019 · AI · contact PI
Evaluating immunity elicited by CD8 T Cell responses targeting invariant epitopes$677,604
R01 · FY2018 · AI · contact PI
Evaluating immunity elicited by CD8 T Cell responses targeting invariant epitopes$677,604
R01 · FY2017 · AI · contact PI
SIV/HIV dysregulation of MAIT cell function impairs anti-M.tb immunity$228,466
R21 · FY2017 · AI · contact PI
NHP Symposium on AIDS - Madison, WI$74,999
R13 · FY2017 · OD · contact PI
Evaluating immunity elicited by CD8 T Cell responses targeting invariant epitopes$681,604
R01 · FY2016 · AI · contact PI
SIV/HIV dysregulation of MAIT cell function impairs anti-M.tb immunity$203,079
R21 · FY2016 · AI · contact PI
Evaluating immunity elicited by CD8 T Cell responses targeting invariant epitopes$686,872
R01 · FY2015 · AI · contact PI
Evaluating immunity elicited by CD8 T Cell responses targeting invariant epitopes$701,872
R01 · FY2014 · AI · contact PI